Overview

A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenstrm's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)

Status:
RECRUITING

Trial end date:
2028-04-11

Target enrollment:

Participant gender:

Summary

The purpose of this study is to find out if the combination of pirtobrutinib, venetoclax, and rituximab is an effective treatment for participants with Waldenstrm's macroglobulinemia (WM)/lymphoplasmacytic lymphoma (LPL)

Phase:

PHASE2

Details

Lead Sponsor:

Memorial Sloan Kettering Cancer Center

Collaborators:

AbbVie
Eli Lilly and Company

Treatments:

pirtobrutinib
Rituximab
venetoclax